Program
AOC 1001
A development code. Also written as “AOC 1001 (del-desiran)” and “Del-desiran (AOC 1001)”.
In Novartis's pipeline, siRNA DMPK knockdown
. Its studies are mostly in Myotonic Dystrophy, led by Novartis.
Furthest: phase 3, since May 8, 20244 company-led studies, 1 open or runningNext primary completion: Oct 2030 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 41 open or running | phase 3since May 8, 2024 | Aug 24, 2021 | Oct 2030phase 3 · NCT07008469 |
- Named in Novartis’s own pipeline as
EWF980 (del-desiran)
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 24, 2021First study: phase 2 study in Myotonic DystrophyFirst studyNCT05027269 · 39 enrolled · United States
- Jul 27, 2022Phase 2 study in Muscular DystrophiesNCT05479981 · 37 enrolled · United States
- May 8, 2024Phase 3 study in Myotonic DystrophyNCT06411288 · 159 enrolled · United States, Canada, Denmark and more
- May 29, 2025Phase 3 study in Myotonic DystrophyNCT07008469 · 199 planned · United States, Canada, Denmark and more
Ahead
- Oct 2030Primary completion: phase 3 study in Myotonic DystrophyNCT07008469
TargetBeta
“siRNA DMPK knockdown”the company's pipeline, read by Claude · source
Other programs on DMPK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| SAR446268 | Sanofi | phase 2 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07008469Myotonic Dystrophy · United States, Canada, Denmark and more | 3 | By invitation | Oct 2030 | 199 |
| NCT06411288Myotonic Dystrophy · United States, Canada, Denmark and more | 3 | Completed | Jul 23, 2026 | 159 |
| NCT05479981Muscular Dystrophies · United States | 2 | Completed | Sep 5, 2025 | 37 |
| NCT05027269Myotonic Dystrophy · United States | 2 | Completed | Feb 14, 2023 | 39 |
How it is read
Names in the registry
- “AOC 1001”, 2 entries
- “AOC 1001 (del-desiran)”, 1 entry
- “Del-desiran (AOC 1001)”, 1 entry
Codes read as this program: AOC1001.
Conditions, from the studies’ own filings
- Myotonic Dystrophy, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.